Cleveland Clinic Biologic Therapies Summit XI 2025

Include: 18 videos + 14 pdfs, size: 5.05 GB

Target Audience: rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians

Information:

About Biologic Therapies Summit XI

This advanced course is designed for healthcare professionals seeking to deepen their understanding of cutting-edge treatments for immune-mediated inflammatory diseases. Participants will critically appraise and integrate clinical data on the efficacy and toxicity of CAR T-cell therapies, cellular therapies, and other advanced treatments, aiming to identify strategies that could achieve long-term remission or cure.

Participants will also investigate and differentiate between infectious complications from biologic therapies and immune-related adverse events associated with checkpoint inhibitor therapies, formulating effective prevention and management strategies. The course will provide an in-depth examination of the mechanism of action of Janus kinase (JAK) inhibitors, their potential toxicities and adverse effects, particularly infection risks, to ensure optimal administration.

Additionally, participants will evaluate the efficacy and safety of IL-17 inhibitors (e.g., secukinumab, ixekizumab) and IL-23 inhibitors (e.g., ustekinumab, guselkumab) in treating immune-mediated inflammatory diseases, assessing the risks, including susceptibility to infections and long-term use implications. The latest advances in IL-23 inhibitors for immune-mediated inflammatory diseases will be explored, with a focus on emerging research and future clinical applications.

Finally, the course will critically evaluate emerging therapeutic strategies for difficult-to-treat conditions such as psoriatic arthritis (PsA), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and inflammatory myopathies, proposing innovative approaches to optimize patient outcomes based on current advancements.

By Attending, You Will Be Able To:

• Critically appraise and integrate clinical data on the efficacy and toxicity of CAR T-cell therapies, cellular therapies, and other advanced treatments, with the objective of identifying and proposing strategies that could lead to long-term remission or cure of immune-mediated inflammatory diseases.
• Investigate and differentiate between infectious complications from biologic therapies and immune-related adverse events associated with checkpoint inhibitor therapies, while formulating effective prevention and management strategies.
• Examine the mechanism of action of Janus kinase (JAK) inhibitors in modulating immune responses, and identify the potential toxicities and adverse effects, particularly infection risks, to ensure the optimal administration of JAK inhibitors in patients.
• Evaluate the efficacy and safety of IL-17 inhibitors (e.g., secukinumab, ixekizumab) and IL-23 inhibitors (e.g., ustekinumab, guselkumab) in treating immune mediated inflammatory diseases, and assess the risks, including susceptibility to infections and the implications of long-term use.
• Explore and interpret the latest advances in IL-23 inhibitors for immune mediated inflammatory diseases, and assess their potential for treating other inflammatory conditions by examining emerging research and future clinical applications.
• Critically evaluate emerging therapeutic strategies for difficult-to-treat psoriatic arthritis (PsA), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and inflammatory myopathies, and propose innovative approaches to optimize patient outcomes based on current advancements.

Who Should Attend?

The Summit is directed towards rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians, nurse practitioners, nurses, and physician assistants interested in or using biologic therapeutics for autoimmune and autoinflammatory disorders.

+ Topics:

Friday, May 9, 2025 – Biologic Therapies Summit XI

• 7:30 am Breakfast, Non-CME Presentation & Registration
• 8:20 am Welcome & Introductions
• Session 1 – Advances in basic and translational immunology for the clinical rheumatologist
• 8:30 am Immune profiling of patients with autoimmune diseases: defining metrics of immunedysregulation Deepak Rao, MD, PhD
• 9:00 am The evolution of immune effector cell therapies for the treatment of autoimmune diseases Maximilian F. Konig, MD
• 9:30 am Panel discussion
• 10:00 am Break & Exhibits
• 10:20 am IL-23 – Advances in basic and clinical immunology Christopher Ritchlin, MD, MPH
• 10:50 am New insights into the role of EBV in autoimmune diseases William Robinson, MD, PhD
• 11:20 am Panel discussion
• 11:50 am Lunch & Non-CME Presentations
• Session 2 – Emerging Treatments in IMIDs
• 1:00 pm Signal and the Noise: Safety in Rheumatology Michael Putman, MD, MSci
• 1:25 pm PsA Christopher Ritchlin, MD, MPH
• 1:50 pm Clinical Insights discussion M. Elaine Husni, MD, MPH; Anthony Fernandez, MD, PhD; Michael Putman, MD, MSCI; Christopher Ritchlin, MD, MPH
• 2:20 pm Difficult to Treat RA (D2TRA) Jack Cush, MD
• 2:50 pm Clinical Insights discussion Jack Cush, MD, and Len Calabrese, DO
• 3:15 pm Break
• 3:35 pm Emerging treatments on Lupus nephritis Michelle Petri, MD, MPH
• 4:05 pm Advances in the treatment of inflammatory myopathies Rohit Aggarwal, MD, MS
• 4:35 pm Clinical Insights Discussion Rohit Aggarwal, MD, MS; Len Calabrese, DO; Emily Littlejohn, DO; Michelle Petri, MD, MPH
• 5:05 pm Adjourn to Reception and Poster Session (non-CME)

Saturday, May 10, 2025

• 7:30 am Breakfast Non-CME Presentation & Registration
• 8:20 am Welcome & Introductions
• 8:30 am Infectious complications from biologic therapy Cassandra Calabrese, DO
• 9:00 am Immune related adverse events from checkpoint inhibitor therapy: targeted therapies Noha Abdelwahab Hassan, MD, PhD
• 9:30 am Discussion Cassandra Calabrese, DO, and Noha Abdelwahab Hassan, MD, PhD
• 10:00 am Break
• 10:20 am Moneyball Rheumatology – Making the most out of our time and data for better care of our patients Jack Cush, MD
• 10:50 am The highs and lows of social media in rheumatology Adam Brown, MD
• 11:20 am Discussion Jack Cush, MD and Adam Brown, MD
• 11:50 am Concluding Remarks
• 12:00 pm Program adjourns